Form 4: Spectrum Equity Reduces GoodRx Holdings Stake

Spectrum Equity entities converted Class B shares to Class A and subsequently sold or distributed a significant portion of their holdings in GoodRx Holdings, Inc.

Summary

• Spectrum Equity VII, L.P., Spectrum VII Investment Managers' Fund, L.P., and Spectrum VII Co-Investment Fund L.P. converted their Class B Common Stock holdings in GoodRx Holdings, Inc. to Class A Common Stock on a one-for-one basis on October 14, 2025.
• Spectrum Equity VII, L.P. subsequently distributed 8,881,362 Class A shares to its general and limited partners for no consideration on October 14, 2025.
• Spectrum VII Investment Managers' Fund, L.P. sold 15,202 Class A shares on October 15, 2025, at a weighted average price of $4.0008 per share.
• Spectrum VII Co-Investment Fund L.P. sold 8,569 Class A shares on October 15, 2025, at a weighted average price of $4.0008 per share.
• Following these transactions, the reporting persons indicated they are no longer subject to Section 16 reporting obligations, suggesting a significant reduction or complete divestment of their beneficial ownership in GoodRx.

Sentiment

Score: 3

Explanation: The filing indicates a significant reduction in beneficial ownership by a major institutional investor (Spectrum Equity), which is generally perceived as a negative signal for the company's stock performance.

Positives

• The transactions represent an orderly exit strategy by a major institutional investor.

Negatives

• Significant insider selling by a 10% owner, Spectrum Equity, can be interpreted as a lack of confidence in the company's future prospects.
• The divestment by a major institutional investor could put downward pressure on the stock price.

Risks

• Negative investor sentiment due to the substantial reduction in ownership by a key institutional investor.
• Potential for increased selling pressure on GoodRx's stock as other investors react to the news.

Future Outlook

NA

Industry Context

This filing reflects an institutional investor's decision to reduce its exposure to GoodRx Holdings, Inc., which may be influenced by broader market conditions, company-specific performance, or portfolio rebalancing strategies within the digital healthcare and pharmaceutical discount industry.

Comparison to Industry Standards

• NA

Related Party Transactions

• Spectrum Equity VII, L.P. made a pro rata distribution of 8,881,362 shares of Class A Shares to its general partner and limited partners for no consideration.

Stakeholder Impact

• Shareholders may interpret the significant reduction in ownership by a major institutional investor as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.

Next Steps

• The reporting persons are no longer subject to Section 16 reporting obligations, though Form 4 or Form 5 obligations may continue under specific circumstances.

Key Dates

Recommendation

The substantial divestment by a major institutional investor and 10% owner, Spectrum Equity, signals a potential lack of confidence in GoodRx's future growth or valuation. Such a large insider exit often precedes periods of underperformance or increased selling pressure, making a 'sell' recommendation prudent for investors seeking to mitigate risk.

Keywords

GoodRx Holdings, GDRX, Spectrum Equity, Insider Selling, Form 4, Stock Sale, Beneficial Ownership, Class A Common Stock, Class B Common Stock, Equity Distribution